Inflammatory Factor Articles & Analysis

4 news found

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Mineralocorticoid receptor (MR) overactivation contributes to CKD progression and CV damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Finerenone offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation. ...

Jun. 22, 2023

ByBayer AG

Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

” Mineralocorticoid receptor (MR) overactivation contributes to CKD progression and CV damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Addressing an alternative pathway, Kerendia offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation. ...

Feb. 10, 2023

ByBayer AG

Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

Dec. 16, 2022

ByBayer AG

New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy

In T2D, MR overactivation is thought to contribute to CKD progression and cardiovascular damage which can be driven by metabolic, hemodynamic or inflammatory and fibrotic factors. The Phase III study program with finerenone, FINEOVATE, currently comprises four Phase III studies: FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF and FIND-CKD. ...

Nov. 8, 2021

ByBayer AG

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you